Pacific Biosciences of California Inc (OQ:PACB)
Business Focus: Advanced Medical Equipment & Technology
| Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 1305 O'brien Drive MENLO PARK CA 94025 |
| Tel: | N/A |
| Website: | https://www.pacb.com |
| IR: | See website |
| Key People | ||
| Christian O. Henry President, Chief Executive Officer, Director | Susan G Kim Chief Financial Officer | Mark Van Oene Chief Operating Officer |
| Michele Farmer Chief Accounting Officer, Vice President | Brett Atkins General Counsel, Corporate Secretary | Jeff Eidel Chief Commercial Officer |
| Business Overview |
| Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time. |
| Financial Overview |
| For the three months ended 31 March 2024, Pacific Biosciences of California Inc revenues decreased less than 1% to $38.8M. Net loss decreased 11% to $78.2M. Revenues reflect Product segment increase from $4.2M to $35M, Consumable revenue segment increase of 15% to $16M, Asia Pacific segment increase of 7% to $12.8M, Europe (including the Middle East and Africa) segment increase of 6% to $8.4M. |
| Employees: | 796 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $813.08M as of Mar 31, 2024 |
| Annual revenue (TTM): | $200.43M as of Mar 31, 2024 |
| EBITDA (TTM): | -$285.27M as of Mar 31, 2024 |
| Net annual income (TTM): | -$296.90M as of Mar 31, 2024 |
| Free cash flow (TTM): | -$249.17M as of Mar 31, 2024 |
| Net Debt Last Fiscal Year: | $331.03M as of Mar 31, 2024 |
| Shares outstanding: | 272,355,892 as of Apr 30, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.